Whole-Exome Sequencing of Acquired Nevi Identifies Mechanisms for Development and Maintenance of Benign Neoplasms
Overview
Authors
Affiliations
The melanoma transformation rate of an individual nevus is very low despite the detection of oncogenic BRAF or NRAS mutations in 100% of nevi. Acquired melanocytic nevi do, however, mimic melanoma, and approximately 30% of all melanomas arise within pre-existing nevi. Using whole-exome sequencing of 30 matched nevi, adjacent normal skin, and saliva we sought to identify the underlying genetic mechanisms for nevus development. All nevi were clinically, dermoscopically, and histopathologically documented. In addition to identifying somatic mutations, we found mutational signatures relating to UVR mirroring those found in cutaneous melanoma. In nevi we frequently observed the presence of the UVR mutation signature compared with adjacent normal skin (97% vs. 10%, respectively). Copy number aberration analysis showed that for nevi with copy number loss of tumor suppressor genes, this loss was balanced by loss of potent oncogenes. Moreover, reticular and nonspecific patterned nevi showed an increased (P < 0.0001) number of copy number aberrations compared with globular nevi. The mutation signature data generated in this study confirms that UVR strongly contributes to nevogenesis. Copy number changes reflect at a genomic level the dermoscopic differences of acquired melanocytic nevi. Finally, we propose that the balanced loss of tumor suppressor genes and oncogenes is a protective mechanism of acquired melanocytic nevi.
EGR3 Inhibits Tumor Progression by Inducing Schwann Cell-Like Differentiation.
Chen C, Chen Y, Li Y, Zhang H, Huang X, Li Y Adv Sci (Weinh). 2024; 11(34):e2400066.
PMID: 38973154 PMC: 11425834. DOI: 10.1002/advs.202400066.
Zhang Y, Ostrowski S, Fisher D Hematol Oncol Clin North Am. 2024; 38(5):939-952.
PMID: 38880666 PMC: 11368644. DOI: 10.1016/j.hoc.2024.05.005.
Harrison S, Buettner P, Nowak M Cancers (Basel). 2023; 15(6).
PMID: 36980647 PMC: 10046807. DOI: 10.3390/cancers15061762.
Muse M, Schaider H, Oey H, Soyer H, Christensen B, Stark M J Invest Dermatol. 2023; 143(9):1830-1834.e6.
PMID: 36958602 PMC: 11195670. DOI: 10.1016/j.jid.2023.03.1653.
Mordoh A, Trivino Pardo J, Carri I, Barrio M, Mordoh J, Aris M BMC Med Genomics. 2023; 16(1):1.
PMID: 36604730 PMC: 9814418. DOI: 10.1186/s12920-022-01426-2.